الفهرس | Only 14 pages are availabe for public view |
Abstract Alzheimer’s disease (AD) is growing as a public health issue, exhibited by aging-related memory impairment and cognitive deficits. This is because the life expectancy of humans increases in technologically advanced societies. Additionally, AD is a fatal neurodegenerative disorder that cannot be reversed. Despite the fact that the number of people with these disorders keeps on increasing, the US Food and Drug Administration (FDA) hasn’t yet found or permitted any medical therapy for dementia. However, the current medications for AD only treat symptoms. The most prevalent sign of neurodegeneration is memory loss, which is caused by dysfunctional and diminished neurons in the tissues of the brain, especially in the hippocampal area (Sohn et al., 2019).The form of dementia that is most prevalent is AD, which is a slowly progressing neurodegenerative condition defined by amyloid-beta (Aβ) deposits and neurofibrillary tangles (NFTs). AD was named after Alois Alzheimer, the German psychiatrist. The neocortical structures and medial temporal lobe, the area of the brain where Aβ deposits are most influenced (Figure 1) (Breijyeh & Karaman, 2020. |